“A multicentre prospective randomised open-label blinded end-point controlled trial of cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients (Cardiac Care).” £38.700 PI: Dr. Peter Henriksen, 2018. (research agreement for developing data analysis protocol for cardiovascular MR data, provide training and supervision of research staff that will implement the analysis protocol, researcher)